News
VSTM
7.22
-2.17%
-0.16
Weekly Report: what happened at VSTM last week (0817-0821)?
Weekly Report · 6d ago
Weekly Report: what happened at VSTM last week (0810-0814)?
Weekly Report · 08/17 09:44
Verastem (VSTM) Q2 2026 Earnings Call Transcript
NASDAQ · 08/13 23:46
Verastem Price Target Cut to $13.00/Share From $14.00 by Mizuho
Dow Jones · 08/11 11:58
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13
Benzinga · 08/11 11:48
Verastem price target lowered to $13 from $14 at Mizuho
TipRanks · 08/11 11:32
Weekly Report: what happened at VSTM last week (0803-0807)?
Weekly Report · 08/10 09:41
Verastem Earnings Call Highlights Cash, Pipeline Momentum
TipRanks · 08/08 00:05
Verastem Price Target Cut to $12.00/Share From $14.00 by Guggenheim
Dow Jones · 08/07 16:56
Verastem Is Maintained at Buy by Guggenheim
Dow Jones · 08/07 16:56
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Benzinga · 08/07 16:46
Verastem price target lowered to $12 from $14 at Guggenheim
TipRanks · 08/07 11:36
RBC Capital Keeps Their Buy Rating on Verastem (VSTM)
TipRanks · 08/07 11:27
At a glance: stocks gapping up premarket
Seeking Alpha · 08/07 11:25
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 08/06 21:40
Press Release: Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Dow Jones · 08/06 20:01
*Verastem 2Q Rev $40.1M >VSTM
Dow Jones · 08/06 20:01
*Verastem 2Q Loss $34.7M >VSTM
Dow Jones · 08/06 20:01
*Verastem 2Q Loss/Shr 35c >VSTM
Dow Jones · 08/06 20:01
Press Release: Verastem Oncology Reports Second -3-
Dow Jones · 08/06 20:01
More
Webull provides a variety of real-time VSTM stock news. You can receive the latest news about Verastem through multiple platforms. This information may help you make smarter investment decisions.
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.